Fig. 4.

P-MSCS imparts significantly higher SCID repopulating ability on expanded CD34⁺ cells than C-MSCs. a,b At four weeks post transplantation (short term engraftment) the bone marrow(a) and spleen(b) of the mice receiving cells expanded on P-MSCs showed a significantly higher percentage of human CD45⁺ cells. Each dot in the graph represents an individual animal. c Representative FACS dot plots showing a higher percentage of human CD45⁺ cells in the BM of NOD/SCID mice infused with cells expanded on P-MSCs on the background of murine CD45⁺ cells. d Donor derived7 multi-lineage engraftment was seen in the BM of NOD/SCID mice for P- and C-MSCs expanded sets as determined by CD34 (stem cells), CD33 (myeloid cells), CD56(NK cells), CD19 (B cells), and CD3 (T cells). e Donor-derived committed progenitors were higher in the BM of mice receiving cells expanded on P-MSCs than on C-MSCs as evaluated by performing an in vitro colony formation assay on MBM using human specific growth factors. f, g Long term engraftment (12 weeks) indicated significantly higher chimerism (% human CD45) was detected in the BM (f) and spleen (g) of NOD/SCID mice receiving cells from P-MSCs co-cultures. h Representative FACS dot plots showing higher percentage of human CD45⁺ cells in BM of NOD/SCID mice infused with cells expanded on P-MSCs in the murine CD45⁺ background after 12 weeks. i, j Serial transplantation assay showed a significantly higher percentage of human CD45⁺ in BM (i) and spleen (j), the secondary recipient receiving cells from mice infused with cells expanded on P-MSCs. k Representative FACS dot plots showing a higher percentage of human CD45⁺ cells in the BM of NOD/SCID mice infused with cells from primary recipient. Data are represented as mean ± standard deviation from ten different mice. (n = 10) *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. P-MSCs placenta-derived mesenchymal stem cells, C-MSCs cord-derived mesenchymal stem cells, FACS fluorescence-activated cell sorting, BM bone marrow